Or register here
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Scientific Articles

Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia

key information

source: Haematologica

year: 2018

authors: Penkert RR, Hurwitz JL, Thomas P, Rosch J, Dowdy J, Sun Y, Tang L, Hankins JS

summary/abstract:

Children with sickle cell anemia (SCA) suffer from a chronic state of inflammation due to repeated tissue insult from sickling red blood cells. The clinical consequences are severe and involve aberration of inflammatory systems, with associated increased activation of multiple cell types, including platelets, neutrophils, and eosinophils.1,2 The literature has described a reduction of inflammatory molecules by hydroxyurea, but results have been limited, and at times contradictory.3–8 In fact, some researchers reported that patients receiving hydroxyurea exhibited increased levels of interleukin (IL)-6 compared to untreated patients,9 while others reported a decrease in IL-6 levels in patients after initiating hydroxyurea therapy,10 albeit neither finding reached statistical significance (perhaps due to small study numbers). Herein, we address discrepancies by reporting a comprehensive study in which 214 patients with SCA were assessed, 122 of whom were sampled longitudinally.

We compared patients on hydroxyurea (both initial and sustained therapy) with patients on chronic blood transfusions or no treatment. In grouped analyses, hydroxyurea proved to be the better treatment for reduction of inflammatory molecules. During the 2-year observation period, children continued to benefit from hydroxyurea treatment, although they did not achieve profiles similar to those of healthy controls. Patients receiving continuous chronic blood transfusion therapy or no treatment showed fewer reductions in factor levels compared to hydroxyurea. In total, our data illustrated the long-term, but incomplete benefit of hydroxyurea for reduction of inflammatory molecules in patients with SCA.

organization: University of Tennessee Health Science Center, USA

DOI: 10.3324/haematol.2017.177360

read more full text

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close